Nephro Trial Files: Veverimer vs. Placebo in CKD and Metabolic Acidosis, Sparsentan vs. Irbesartanin IgA Nephropathy, and Hypertension Treatment During Pregnancy
Nephro Trial Files: Veverimer vs. Placebo in CKD and Metabolic Acidosis, Sparsentan vs. Irbesartanin IgA Nephropathy, and Hypertension Treatment During Pregnancy
nephrotrialfiles.substack.com
VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis Tangri N et al. JASN (January 2024) Bottom Line: This is a Phase 3, double-blind, placebo-controlled trial with a duration of 24 months. The study aimed to determine if treatment with veverimer, a hydrochloric acid binder, could slow chronic kidney disease (CKD) progression in patients with CKD and metabolic acidosis. The study included 1480 participants from 35 countries who were randomized to receive either veverimer or placebo. The primary outcome was the composite endpoint of CKD progression, which was not significantly different between the two groups. The study found no significant difference in safety outcomes between the groups. In conclusion, treatment with veverimer did not slow CKD progression in this patient population.
Nephro Trial Files: Veverimer vs. Placebo in CKD and Metabolic Acidosis, Sparsentan vs. Irbesartanin IgA Nephropathy, and Hypertension Treatment During Pregnancy
Nephro Trial Files: Veverimer vs. Placebo in…
Nephro Trial Files: Veverimer vs. Placebo in CKD and Metabolic Acidosis, Sparsentan vs. Irbesartanin IgA Nephropathy, and Hypertension Treatment During Pregnancy
VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis Tangri N et al. JASN (January 2024) Bottom Line: This is a Phase 3, double-blind, placebo-controlled trial with a duration of 24 months. The study aimed to determine if treatment with veverimer, a hydrochloric acid binder, could slow chronic kidney disease (CKD) progression in patients with CKD and metabolic acidosis. The study included 1480 participants from 35 countries who were randomized to receive either veverimer or placebo. The primary outcome was the composite endpoint of CKD progression, which was not significantly different between the two groups. The study found no significant difference in safety outcomes between the groups. In conclusion, treatment with veverimer did not slow CKD progression in this patient population.